Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Xevinapant in Healthy East Asian Participants
NCT05519540Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of xevinapant in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Sample Time, Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity and 1 more. Started Sep 2022; status: completed.
02
Drugs
xevinapant
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05519540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05519540.